Table 4. Comparisons of treatment outcomes between AdV and non-AdV pneumonia.
| Characteristics | Total (n = 324) | AdV (n = 166) | Non-AdV (n = 158) | P value |
|---|---|---|---|---|
| Treatment regimens | < 0.001 | |||
| Initial empirical antibiotics | ||||
| Amoxicillin and clavulanate | 5 (1.5) | 4 (2.4) | 1 (0.6) | |
| 3rd-cephalosporin + azalide | 133 (41.1) | 47 (28.4) | 86 (54.5) | |
| 3rd-cephalosporin + respiratory quinolone | 1 (0.3) | - | 1 (0.6) | |
| Respiratory quinolone | 75 (23.2) | 45 (27.1) | 30 (19.0) | |
| Piperacillin/tazobactam | 22 (6.8) | 16 (9.6) | 6 (3.8) | |
| Piperacillin/tazobactam + azalide | 3 (0.9) | - | 3 (1.9) | |
| Piperacillin/tazobactam + respiratory quinolone | 82 (25.3) | 52 (31.3) | 30 (19.0) | |
| Carbapenem | 3 (0.9) | 2 (1.2) | 1 (0.6) | |
| Antiviral agents (cidofovir, 5 mg/kg/week) | 34 (20.5) | - | NA | |
| No. of cidofovir administration | ||||
| 1 | - | 29/34 | - | |
| 2 | - | 5/34 | - | |
| Adjuvant IVIG | 16 (4.9) | 14 (8.4) | 2 (1.3) | 0.002 |
| High flow nasal cannula | 13 (4.0) | 8 (4.8) | 5 (3.2) | 0.575 |
| Mechanical ventilation | 6 (1.9) | 6 (3.6) | - | 0.03 |
| ECMO | 1 (0.3) | 1 (0.6) | - | 0.999 |
| Respiratory failure during hospitalization | 50 (15.4) | 37 (22.3) | 13 (8.2) | 0.001 |
| Initial respiratory failure | 34 (10.5) | 23 (13.9) | 11 (7.0) | |
| Progressed to respiratory failure | 16 (4.9) | 14 (8.4) | 2 (1.3) | |
| Time to overall clinical stabilization from admission, day | 3.3 ± 2.5 | 3.8 ± 2.8 | 2.6 ± 1.9 | < 0.001 |
| Death | 1 (0.3) | 1 (0.6) | 0.999 |
Data are shown as mean ± standard deviation or number (%).
AdV = adenovirus, CT = computed tomography, ECMO = extracorporeal membrane oxygenation, IVIG = intravenous immunoglobulin, NA = not applicable.